AUS
NZ
UK
CA
USA
IND
_07_03_2026_03_50_21_133108.jpg)
_10_04_2024_16_38_50_427275.jpg)
Paradigm Biopharmaceuticals Limited (ASX:PAR) has completed the conversion of 900,000 convertible notes into 9,437,229 ordinary fully paid shares, issued on 17 July 2026. These convertible notes (PARAAD) were converted at an issue price of AUD 0.15 per share, increasing the company’s quoted equity capital. This transaction is part of Paradigm’s ongoing capital management strategy to convert debt-like instruments into equity.
Key Points
- Paradigm Biopharmaceuticals Limited (PAR) applied for quotation of 9,437,229 ordinary fully paid shares issued on 17 July 2026
- The shares resulted from converting 900,000 convertible notes (PARAAD) at AUD 0.15 per share
- Post-quotation, PAR’s total quoted ordinary shares will reach 594,280,824
- The company retains unquoted securities including 11,127,100 performance rights, 3,000,000 options expiring 30 June 2027, and 7,547,185 outstanding convertible notes
Details of Convertible Note Conversion and Timeline
Paradigm Biopharmaceuticals finalized the conversion of 900,000 convertible notes (PARAAD) into ordinary shares, with the conversion process concluding on 17 February 2026 and the shares issued and applied for ASX quotation on 17 July 2026. The shares were issued at AUD 0.15 each, creating 9,437,229 new ordinary fully paid shares. These shares carry identical rights and entitlements as existing ordinary shares, ensuring equal ranking among shareholders.
Effect on Paradigm’s Capital Structure
Following this issuance, Paradigm’s quoted ordinary share capital totals 594,280,824 shares alongside 117,069,101 options expiring 1 December 2026. This conversion increased the quoted share capital by approximately 1.6%, reflecting the company’s strategy of raising capital and converting debt instruments into equity. The company also holds significant unquoted securities, including 11,127,100 performance rights, 3,000,000 options expiring 30 June 2027 at AUD 0.65 exercise price, 151,293 options expiring 11 February 2028 at AUD 1.00 exercise price, and 7,547,185 remaining convertible notes (PARAAD).
Outstanding Convertible Notes and Future Conversion Potential
Despite converting 900,000 notes, Paradigm still has 7,547,185 convertible notes outstanding as unquoted securities. This indicates that the recent conversion is partial, with further conversions possible in the future depending on instrument terms. The staged conversion approach allows the company to manage its capital structure progressively while aligning with market conditions and corporate milestones. Investors should monitor potential future conversions, as they could affect share dilution and equity structure.
Performance Rights and Unquoted Options Overview
Paradigm holds 11,127,100 performance rights, typically granted subject to performance or vesting conditions, commonly used for employee incentives. Additionally, the company has two classes of unquoted options: 3,000,000 options expiring 30 June 2027 with an exercise price of AUD 0.65, and 151,293 options expiring 11 February 2028 with an exercise price of AUD 1.00. These instruments may lead to future dilution if exercised, reflecting layered incentive schemes aligned with company objectives.
Industry Context and Capital Raising Practices
Operating in the biopharmaceutical sector, Paradigm uses convertible notes and hybrid securities to manage capital needs amid high R&D costs and long development cycles. Conversion of these instruments into equity often aligns with milestone achievements or valuation triggers. Performance rights and options are standard tools to incentivize management and employees, linking rewards to company performance and milestones.
Currency and Pricing Details
The conversion price of AUD 0.15 per share aligns with Paradigm’s Australian listing on the ASX. This fixed conversion price is consistent with terms embedded in the original convertible note agreements, facilitating transparent capital management. Understanding these pricing points helps investors assess the company’s valuation trends and investor sentiment over time.
ASX Listing Compliance and Quotation Application
Paradigm submitted its application for quotation of the 9,437,229 shares under ASX Listing Rules via Appendix 2A, confirming these shares arise from conversion of existing securities rather than a new class. This ensures the shares are formally listed and freely tradable on the ASX, providing clarity and liquidity for investors and accurately reflecting the expanded equity base.
Shareholder Dilution and Capitalization Impact
The issuance of nearly 9.4 million new shares represents a 1.6% increase in quoted share capital, a typical dilution effect from convertible note conversions in biopharmaceutical firms. Existing shareholders at the time of note issuance would have anticipated this dilution, but newer shareholders may experience a reduction in ownership percentage. Investors should consider outstanding convertible securities when evaluating potential dilution risks.
Investor Guidance and Monitoring
With ASX approval, the newly converted shares are now tradable alongside existing shares. While this tranche’s conversion is complete, Paradigm retains 7,547,185 convertible notes that may convert in the future. Investors should monitor quarterly reports and shareholder notices for updates on further conversions or option exercises. Tracking the exercise of 3,000,000 options expiring 30 June 2027 and vesting of 11,127,100 performance rights is also recommended, as these could lead to additional share issuances and dilution. Monitoring Paradigm’s financial and strategic progress will provide insight into capital structure decisions and conversion timing.
